[go: up one dir, main page]

WO2013049591A3 - Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci - Google Patents

Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci Download PDF

Info

Publication number
WO2013049591A3
WO2013049591A3 PCT/US2012/057951 US2012057951W WO2013049591A3 WO 2013049591 A3 WO2013049591 A3 WO 2013049591A3 US 2012057951 W US2012057951 W US 2012057951W WO 2013049591 A3 WO2013049591 A3 WO 2013049591A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
inhibitor compounds
factor
dual inhibitor
activated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2012/057951
Other languages
English (en)
Other versions
WO2013049591A2 (fr
Inventor
Kevin Michael Short
Son Minh Pham
David Charles Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Verseon Corp
Original Assignee
Verseon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verseon Corp filed Critical Verseon Corp
Publication of WO2013049591A2 publication Critical patent/WO2013049591A2/fr
Publication of WO2013049591A3 publication Critical patent/WO2013049591A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne inter alia des composés aromatiques multisubstitués qui montrent une double action inhibitrice contre la thrombine (facteur II activé de coagulation du sang; EC 3.4.21.5) et le facteur de coagulation Xa (facteur Stuart-Prower activé, facteur Xa, EC 3.4.21.6), et le procédé d'utilisation de ceux-ci.
PCT/US2012/057951 2011-09-29 2012-09-28 Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci Ceased WO2013049591A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161540653P 2011-09-29 2011-09-29
US61/540,653 2011-09-29

Publications (2)

Publication Number Publication Date
WO2013049591A2 WO2013049591A2 (fr) 2013-04-04
WO2013049591A3 true WO2013049591A3 (fr) 2013-05-23

Family

ID=47996765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/057951 Ceased WO2013049591A2 (fr) 2011-09-29 2012-09-28 Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci

Country Status (1)

Country Link
WO (1) WO2013049591A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
CA2902431A1 (fr) 2013-03-15 2014-09-25 Kevin Michael Short Halogenopyrazoles en tant qu'inhibiteurs de la thrombine
EP3421036B8 (fr) 2013-03-15 2020-12-30 Verseon International Corporation Composés aromatiques multisubstitués en tant qu'inhibiteurs de sérine protéase
EP3004095A1 (fr) * 2013-06-03 2016-04-13 Bayer Pharma Aktiengesellschaft Triazolopyridines utilisées comme inhibiteurs de la thrombine pour traiter des maladies thromboemboliques
BR112017003918B1 (pt) 2014-08-29 2022-05-03 Fmc Corporation Composto, composições e mistura herbicida e método para o controle do crescimento da vegetação
RU2017112739A (ru) * 2014-09-17 2018-10-17 Версеон Корпорейшн Пиразолил-замещенные пиридоновые соединения как ингибиторы сериновых протеаз
SG11201706411YA (en) * 2015-02-27 2017-09-28 Verseon Corp Substituted pyrazole compounds as serine protease inhibitors
WO2017152842A1 (fr) * 2016-03-10 2017-09-14 National Institute Of Biological Sciences, Beijing Inhibiteurs de kinases
CA3228394A1 (fr) * 2021-08-10 2023-02-16 Avinash BOPPANA Compositions, formulations et methodes de traitement capillaire
US12251459B2 (en) 2022-10-12 2025-03-18 Oddity Labs, Llc Compositions, formulations, and methods for hair treatment
WO2024123668A1 (fr) * 2022-12-05 2024-06-13 Oddity Labs, Llc Compositions, formulations et méthodes de traitement capillaire

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256887A (en) * 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
WO2000010563A1 (fr) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
WO2004046120A2 (fr) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
US20100196357A1 (en) * 2008-02-20 2010-08-05 Qihong Huang Microrna modulators and method for identifying and using the same

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4256887A (en) * 1978-04-06 1981-03-17 Merck & Co., Inc. 1,2,4-Triazoles and a method for their preparation
WO2000010563A1 (fr) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Nouveaux composes de triazole substitues
WO2004046120A2 (fr) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
US20100196357A1 (en) * 2008-02-20 2010-08-05 Qihong Huang Microrna modulators and method for identifying and using the same

Also Published As

Publication number Publication date
WO2013049591A2 (fr) 2013-04-04

Similar Documents

Publication Publication Date Title
WO2013049591A3 (fr) Composés doublement inhibiteurs et procédés d'utilisation de ceux-ci
WO2011115712A3 (fr) Inhibiteurs de tfpi et procédés d'utilisation associés
WO2011133875A3 (fr) Composés inhibiteurs de métalloenzyme
WO2012177603A3 (fr) Composés inhibiteurs de métalloenzymes
WO2012004678A3 (fr) Inhibiteurs de la sérine protéase
EA200900091A1 (ru) Новые показания к применению прямых ингибиторов тромбина в лечении сердечно-сосудистых заболеваний
WO2012064943A3 (fr) Composés inhibiteurs de métalloenzymes
WO2011138328A3 (fr) Utilisation de molécules inhibitrices pour le traitement d'une hypertension artérielle pulmonaire
EP2607348B8 (fr) Agent inhibiteur de l'inhibiteur de l'activateur du plasminogène 1
WO2011082245A3 (fr) Composés inhibiteurs de métallo-enzyme
PH12013502622A1 (en) Metalloenzyme inhibitor compounds
WO2011094496A3 (fr) Inhibiteurs de sérine protéase de type trypsine, et leur préparation et utilisation
GEP20156341B (en) Anticoagulant antidotes
IL243989A0 (en) Polysubstituted aromatic compounds as thrombin inhibitors
WO2009036175A3 (fr) Inhibiteur de f1f0-atpase et procédés associés
EP2760827A4 (fr) Antiviraux à large spectre contre des protéases 3c ou 3c-associées du super-groupe des picornavirus-associés : picornavirus, calicivirus et coronavirus
WO2009012280A3 (fr) Inhibiteurs de la benzimidazole poly(adp-ribose) polymérase
EP2290370B8 (fr) Procédé permettant de déterminer la cause responsable de la prolongation du temps de coagulation sanguine
WO2012065139A3 (fr) Inhibiteurs de entpd5
WO2010030983A3 (fr) Inhibiteurs pyrazole carboxamide du facteur xa
WO2012065019A3 (fr) Inhibiteurs pyridopyrimidinone de p13k alpha
WO2010053573A3 (fr) Criblage d'inhibiteurs de filovirus et leurs utilisations
WO2009158031A3 (fr) Procédés et compositions pour traitement thérapeutique
WO2012151575A3 (fr) Méthode de maîtrise de la coagulation
CR20140380A (es) Inhibidores de pirazolopirimidinilo de enzima activadora de ubiquitina

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12835962

Country of ref document: EP

Kind code of ref document: A2